These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 30642444)

  • 41. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis.
    Mokhles S; Verstegen N; Maat AP; Birim Ö; Bogers AJ; Mokhles MM; Lagerwaard FJ; Senan S; Takkenberg JJ
    Lung Cancer; 2015 Mar; 87(3):283-9. PubMed ID: 25622781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients.
    Dworzecki T; Idasiak A; Syguła D; Dworzecka U; Suwiński R
    Neoplasma; 2012; 59(1):114-20. PubMed ID: 22103905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019.
    Ashworth A; Kong W; Owen T; Hanna TP; Brundage M
    Radiother Oncol; 2024 May; 194():110153. PubMed ID: 38364940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis.
    Paul S; Lee PC; Mao J; Isaacs AJ; Sedrakyan A
    BMJ; 2016 Jul; 354():i3570. PubMed ID: 27400862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
    Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
    Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
    Wink KCJ; Löck S; Rossi M; van Baardwijk A; Belderbos J; de Ruysscher D; Troost EGC
    Radiother Oncol; 2019 Feb; 131():120-126. PubMed ID: 30773178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Zheng Y; Shi A; Wang W; Yu H; Yu R; Li D; Xu B; Ma H; You J; Zhao D; Jiang L; Geng J; Zhu G
    Clin Lung Cancer; 2018 Jul; 19(4):e399-e404. PubMed ID: 29519614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
    Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.
    Werner-Wasik M; Scott C; Cox JD; Sause WT; Byhardt RW; Asbell S; Russell A; Komaki R; Lee JS
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1475-82. PubMed ID: 11121651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
    Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery.
    Taylor NA; Liao ZX; Stevens C; Walsh G; Roth J; Putnam J; Fossella F; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):616-25. PubMed ID: 12788166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retrospective comparison of stereotactic body radiotherapy versus intensity-modulated radiotherapy for stage III ultra-central squamous non-small-cell lung cancer.
    Cong Y; Xuan L; Sun B; Wang J; Meng X; Zhang J; Xue J; Liu J; Shen G; Wu S
    Future Oncol; 2019 Jun; 15(16):1855-1862. PubMed ID: 30950297
    [No Abstract]   [Full Text] [Related]  

  • 55. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies.
    Chen H; Laba JM; Boldt RG; Goodman CD; Palma DA; Senan S; Louie AV
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):186-194. PubMed ID: 29619964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy.
    Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L
    Radiat Oncol; 2016 Jul; 11():92. PubMed ID: 27411944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
    Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
    Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.
    Chan ST; Ruan D; Shaverdian N; Raghavan G; Cao M; Lee P
    Clin Lung Cancer; 2020 Mar; 21(2):136-144.e1. PubMed ID: 31932217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.